Compare Lamb Weston Holdings Inc (LW) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Merck & Co., Inc. — how do they compare? Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 51.6× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Merck & Co., Inc. for 98 Days on average.
| LW | MRK | |
|---|---|---|
Market Cap | $6.81B | $351.28B |
Volume | 4,638,686 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $156.43 |
52-Week Low | $38.48 | $82.49 |
Typical Hold Time | 66 Days | 98 Days |
Enterprise Value | $10.61B | $398.04B |
Dividend Yield | 3.07% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $49.46, up 2.85% today, showing strong momentum with four consecutive earnings beats. The stock maintains a bullish technical signal with support at $49 and resistance at $50. Fundamentals show solid revenue growth from $4.1B in 2022 to $6.45B in 2025, though net margins compressed from 18.85% to 3.85%. Analyst consensus is mixed with 31.58% Buy ratings and a $53.71 price target, representing 8.6% upside potential.
LW offers potential through continued earnings outperformance and margin recovery initiatives, but faces risks from profit margin volatility and ongoing legal scrutiny. The stock's current valuation at 27x P/E appears reasonable given growth prospects, though investors should monitor execution on the Focus to Win cost-saving strategy and resolution of fiduciary investigation concerns.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
